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Leveraging Social Media to Change the Public Conversation on Lung Cancer Stigma L. Carter-Harris IU Melvin and Bren Simon Cancer Center, Indiana University School of Nursing, Indianapolis/US The reality of lung cancer stigma is tangible and has a profound impact on people living with this disease. Further, stigma remains a highly significant barrier to fulfilling the clinical promise of advancements in lung cancer treatment, early detection, and reduced lung cancer burden. 1-2 Lung cancer stigma can have far-reaching effects that range from reduced involvement in interventions targeting prevention and early detection efforts such as smoking cessation and screening, impaired patient-clinician communication, delayed access to diagnosis and treatment, negative psychosocial responses, and even more broadly, to limited public support of and actual research funding. The phenomenon of lung cancer stigma is multilevel involving that of the individual, persons in the individuals' immediate environment, persons in the healthcare system, and society at large, which shapes public perceptions and decisions that impact lung cancer patients (e.g., public attitudes, media campaigns, policy, research funding). Stigma is mainly social in nature. It is commonly a perceived or felt stigma as well as internalized by the individual patient influencing patient behavior. The stigma of lung cancer is perpetuated by the public's perception that this is a 'smoker's only' disease. However, many people are not aware that approximately 20% of lung cancer patients diagnosed each year are never smokers. 3 It is imperative that innovative and novel approaches to changing the public perception of lung cancer and its associated stigma are pursued. If you have lungs, you can get lung cancer. As opposed to the prevailing perspective of blame that highlights a lifestyle choice fueled by addiction (i.e., smoking), we need to change the public conversation around lung cancer to one that focuses on early diagnosis, treatment, research dollars that match the magnitude of this deadly disease, and compassion. Comprehensive tobacco control efforts over the past five decades have been lauded as one of the leading public health successes. Specifically, restrictions to smoking in public buildings and spaces, increased tobacco-related taxation, and public health national media campaigns primarily delivered through fear-based messaging have all led to diminished social acceptance of smoking as an appropriate lifestyle behavior. Collectively, this has contributed to the overall success of decreasing U.S. adult smoking rates from 43% in 1964 to the current 15.5% U.S. adult smoking rate. 4 Unfortunately, the demonization of tobacco has had the unintended consequence of stigmatizing the disease of lung cancer negatively impacting those at risk for and living with the disease. Just as the stigmatization of lung cancer did not happen in isolation, addressing this phenomenon requires broad strokes, so to speak, to change the public conversation about lung cancer. We have a unique opportunity to leverage social media platforms like Twitter, Facebook, and Instagram to change this conversation by crafting messaging that empowers rather than further stigmatizes both patients living with lung cancer as well as those at risk. The purpose of this presentation will be to discuss: (1) social media as a platform to change the public dialogue around lung cancer, and subsequently, its associated stigma; (2) how successful traditional population-based marketing can be adapted to the social media platform to target stigma; and (3) Rates vary within and across countries. The UK has approximately 2700 new diagnosis a year, one of the highest internationally. Rates of MPM show no signs of reducing and global incidence and burden is likely to be underreported due to poor data capture in some countries. Whilst asbestos use has drastically reduced in developed countries, significant amounts of asbestos are still used in India, China, Russia, and some developing countries (Frank and Joshi 2016) The latency period for MPM varies from 30 and 50 years with an average of 40. Occasionally exposure to diagnosis can be 10 years or less, but this is uncommon. MPM is an incurable cancer but there are new treatments offering promise in terms of length of life and palliation of symptoms. New radical surgical procedures are being performed and novel drug treatments provide better patient outcomes. In addition there are new procedures for the consequences of MPM such as trapped lung and malignant pleural effusion (MPE). Although showing no signs of the global burden reducing, and the increase of new treatment and procedures, there is little research exploring the experience of living with mesothelioma from the perspective of the person with the disease and their family. This presentation will shine a light on existing research, and provides us with an understanding of the experiences of living with MPM. It will draw on the wider literature as well as recent and current studies being conducted by the author and colleagues. International literature will be included but many references will be to the UK context. The journey of the person with MPM will provide the structure for the presentation. Starting with the long road to diagnosis, the experiences of coming to terms with and understanding the diagnosis will be considered. This will be followed by research on people's experiences of treatment and trials and care related to end of life. An underpinning theme will be balancing the bleak with the positive. The diagnostic process is a challenging experience for patients. Many people describe it as a long and winding road, full of dead ends and false trails, as other possible diagnosis are offered prior to confirmation of MPM. For others whose first symptom is a MPE the distress of the symptoms are compounded by the shock of being delivered a terminal diagnosis. Although challenging, for some actually getting a diagnosis confirmed has the benefit of the end of uncertainty. Understanding and coming to terms with a MPM diagnosis is fraught and perplexing. Not only is the diagnosis life limiting, it was due to exposure to asbestos many years ago. The extent to which people remember and expected consequences of this exposure will impact upon ability to accept the diagnosis. It is not uncommon for people to have never heard of MPM and people can struggle to understand the nature of the tumour and their prognosis. Many people see cancer as a solid tumour or lump, so a diffuse cancer such as MPM is difficult for people to understand. Balancing the needs of patients and family members can be difficult especially if they conflict in terms of the nature of information and the time in the pathway it is requested. Prognostic facts are an example as patients and family carers may differ when and if they want such information. For those with a MPE, there is an urgency to have that treated. Unless the MPE and related symptoms are addresses, people are unable to assimilate information about the underlying diagnosis of MPM. This highlights the importance of timing related to information delivery. As new treatments become available, this will increase the information burden for patients. There are also challenges regarding decision making and tolerating the burden of treatments and interventions (Hughes and Arber 2008, Clayson et al 2005) . People will have to understand procedures and eligibility criteria for treatments and face the consequences of being eligible or not eligible. Finding themselves not eligible can be experienced as a 'failure' as well as a loss of hope. For those receiving aggressive treatments they will have to endure any potential side effects and consequences. Legal and compensation processes add additional challenges to the patient journey. Again there may be a time pressure for people to resolve this for family members before the person with MPM dies (Hughes and Arber 2008). Finally research findings regarding end of life are considered, including the access to timely palliative care, pressures on family members in coping with MPM as an industrial disease requiring postmortem and coroner involvement (Clayson et al 2005) . Psychosocial impacts emerge across the pathway as patient's and carers deal with stress, shock, changes to identify, relationships and the demands of managing uncertainty. Throughout the pathway, research indicates the need for people with MPM to balance out the bleak with the positive (Taylor 2018). Understanding this can help health professionals better meet the needs of patients and family. Much of the research on MPM experience highlights the enormity and range of information people have to take on board. Some of this has a time pressure as it is linked to treatment or trial decisions. In conclusion, the contribution of Relationship-centred care' (RCC) will be considered. This expands on and enhances the notion of person-centred care. The proposition is that RCC will help address the complex and challenging nature of improving the MPM patient and carer experiences (Taylor et al 2018) . The experience of patient and family carers experiences of MPM is relatively unexplored. We need more evidence to help us understand what is important to them and how care priorities can best be met. At the impact of increased asbestos use in developing countries emerges, with an increase in asbestos related diseases, research to illuminate patients perspectives and experiences in those nations will be required. Keywords: patient experience, Mesothelioma, quality of life ES08.02 Immunotherapy S. Lantuejoul Biopathology Dept, Centre Léon Bérard, Centre Léon Bérard Unicancer and Grenoble Alpes University, Lyon/FR Lung cancer is the leading cause of cancer death worldwide with low response rates to conventional chemotherapy. Nevertheless, new therapies have emerged recently based on PD-1 immunity check point inhibitors, such as nivolumab and pembrolizumab, or PD-L1 inhibitors, such as atezolizumab, durvalumab, and avelumab. Numerous standardized PD-L1 assays performed on dedicated platforms have been validated in clinical trials, each antibody being associated to one specific PD1 or PD-L1 inhibitor. The prescription of pembrolizumab for advanced stages non-small cell lung carcinoma (NSCLC) patients requires the demonstration of PDL1 expression by tumor cells immunohistochemistry (IHC) (minimum of 50% of positive tumor cells is required for first-line setting, and of 1% for second-line and beyond) and PD-L1 assay is now considered as a companion diagnostic tool for this drug. To date, four standardized PD-L1 immunohistochemistry Dx assays are available: 22C3 and 28-8 pharmDx assays on Dako platforms, and SP142 and SP263 on Ventana platforms; each assay was developed in combination with a particular anti-PD-1 or anti-PD-L1 drug for testing of patients in clinical trials (pembrolizumab, nivolumab, atezolizumab and durvalumab, respectively). These assays differ in terms of characteristics of the primary monoclonal antibodies, the immunohistochemistry platform type, the detection system used, the interpretation of staining and the relevant positivity thresholds identified in clinical trials. Several recent studies have shown a close analytical performance of the 22C3, 28-8 and SP263 assays with respect to tumor cells staining in NSCLC, whereas the SP142 assay stained a lower percentage of tumor cells. These results lead to the conclusions that 22C3, 28-8 and SP263 were interchangeable tests for PD-L1 expression assessment in tumor cells (ref 1-7) . Accordingly, SP263 assay has been proved by the FDA as a complementary diagnostic test for nivolumab and companion diagnostic tests for pembrolizumab in NSCLC. However, not all pathologists have access to the dedicated platforms and the high cost of these assays is still a limitation to their implementation; in addition, the small size of the NSCLC tumor samples does not allow to perform at the same time multiple assays for
